Moteur de recherche d’entreprises européennes
Financement de l’UE (6 499 572 €) : Tester la valeur d’une nouvelle approche stratégique et son rapport coût-efficacité pour améliorer les mauvais résultats en cas de choc cardiogénique Hor 01/01/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Tester la valeur d’une nouvelle approche stratégique et son rapport coût-efficacité pour améliorer les mauvais résultats en cas de choc cardiogénique
Heart attacks are common and can leave survivors suffering cardiogenic shock (CGS), with its extremely high risk of early death (42% versus 4% for non-CGS) and high incidence of chronic heart failure, with its associated socio-economic disease burden (ill-health, recurrent heart failure admissions, no return to full time activities, need for expensive therapeutic devices and life-long drugs). Outcomes from CGS are even worse in, females, the elderly (mortality>70%) and high risk sub-groups. The incidence of CGS in Europe alone is >50 000 patients pa. This unacceptably high mortality/morbidity rate represents a true unmet clinical need. No clear strategy exists to improve outcomes, with ad hoc therapies given too late in a spiralling, irrecoverable process. EURO SHOCK aims to improve outcomes for CGS patients. At its core is a robust phase3 randomised trial comparing a novel strategy of very early use of ECMO (Extracorporeal Membrane Oxygenation) to current standard of care. Evidence suggests very early ECMO will halt the spiral of decline and so significantly reduce 12 month death rate and need for heart failure re-admissions. Since both costs of CGS, and ECMO are high a health-economic cost efficacy analysis will be core. A cardiac magnetic resonance imaging sub-study will test novel protocols in sick patients and provide mechanistic data. We will test transfer networks for CGS patients and analyse ECG data to determine which patients benefit most from early transfer. Our multidisciplinary consortium comprises renowned physician-scientists, statisticians, health economists and technology providers, including specialised ECMO SME. EURO SHOCK will impact on heart attack survivors, healthcare providers and Europe`s medical technology sector by 1) reducing healthcare costs associated with CGS 2) provide novel cost effective framework for cardiac interventions 3) delivering innovative healthcare technologies and 4) informing guidelines for effective CGS intervention.
| Accelopment Schweiz AG | 421 172 € |
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII | 252 375 € |
| Centre Europeen de Recherche Cardiovasculaire Cerc | 320 000 € |
| Chalice Medical Ltd. | 793 750 € |
| Deutsches Herzzentrum Munchen | 252 500 € |
| Fondazione Per LA Ricerca Ospedale Maggiore DE Bergamo | 0,00 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 360 813 € |
| Greater Glasgow Health Board | 0,00 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Katholieke Universiteit Leuven | 517 400 € |
| Ludwig-Maximilians-Universitaet Muenchen | 252 500 € |
| Paula Stradina Kliniska Universitates Slimnica | 82 500 € |
| Universitair Ziekenhuis Antwerpen | 252 500 € |
| Universitat Politecnica de Catalunya | 148 440 € |
| Universitetet I Tromsoe - Norges Arktiske Universitet | 14 496,25 € |
| Universitetssykehuset Nord-Norge HF | 289 254 € |
| University Hospitals of Leicester NHS Trust | 0,00 € |
| University of East Anglia | 267 718 € |
| University of Glasgow | 1 327 844 € |
| University of Leicester | 946 312 € |
https://cordis.europa.eu/project/id/754946
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.